Please use this identifier to cite or link to this item: 10.3390/jcm12196390
Title: National Trends in the Use of State-Reimbursed Lipid-Lowering Medications in Latvia (2012–2021)
Authors: Praskilevics, Arturs
Urtane, Inga
Latkovskis, Gustavs
Department of Pharmaceutical Chemistry
Red Cross Medical College of Rīga Stradiņš University
Keywords: dyslipidemia;ezetimibe;fenofibrate;fixed-dose combination;lipid-lowering medications;PCSK9 inhibitors;statins;trends;3.1 Basic medicine;1.1. Scientific article indexed in Web of Science and/or Scopus database;General Medicine
Issue Date: Oct-2023
Citation: Praskilevics , A , Urtane , I & Latkovskis , G 2023 , ' National Trends in the Use of State-Reimbursed Lipid-Lowering Medications in Latvia (2012–2021) ' , Journal of clinical medicine , vol. 12 , no. 19 , 6390 . https://doi.org/10.3390/jcm12196390
Abstract: Background. We aimed to estimate the trends in dispensing rate and the spectrum of all state-funded lipid-lowering medications (LLMs) in Latvia over a decade. Methods. Using data from the National Health Service of the Republic of Latvia, we retrospectively analyzed all dispensed LLM-containing drug units in a ten-year period from 2012 to 2021. Results. In Latvia, 318.2 million oral and 994 subcutaneous units of LLMs were dispensed over a decade. Statins were the most dispensed LLMs (94.5%), and their use doubled from 19.7 to 43.5 million units. The proportion of high-intensity statins increased from 31.3% to 45.2%. The dispensing rate of ezetimibe increased from 184.7 thousand to 4.8 million. The share of fixed-dose statin combinations with ezetimibe grew from 0.2% to 10.0% among all statins and from 22.2% to 90.9% among all ezetimibe units. Statin use for primary and secondary prevention increased from 7.0 to 19.9 million and from 12.8 to 23.6 million units, respectively. Conclusion. The dispensing rate of statins doubled, and the use of ezetimibe increased more than 25 times in Latvia over a decade. The proportion of high-intensity statins increased from one third to almost half of all statins. Fixed-dose statin combinations with ezetimibe became frequently used.
Description: Publisher Copyright: © 2023 by the authors.
DOI: 10.3390/jcm12196390
ISSN: 2077-0383
Appears in Collections:Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure

Files in This Item:
File SizeFormat 
jcm-12-06390.pdf3.21 MBAdobe PDFView/Openopen_acces_unlocked


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.